Guardant Health

Guardant Health

Blood-based tests for cancer detection and management

About Guardant Health

Simplify's Rating
Why Guardant Health is rated
A-
Rated A on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2012

Overview

Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their main product, Guardant360, is an FDA-approved test that helps healthcare providers make informed treatment decisions for patients with advanced cancer. The tests work by analyzing blood samples to detect and monitor cancer, allowing for non-invasive diagnostics. Unlike many competitors, Guardant Health focuses on providing data-rich insights that can guide treatment from early detection to advanced disease management. The company's goal is to enhance patient outcomes and lessen the impact of cancer through innovative diagnostic solutions.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for non-invasive diagnostics boosts Guardant Health's market potential.
  • Partnerships with pharma firms like Boehringer Ingelheim expand their companion diagnostics portfolio.
  • Legal victory against Natera strengthens Guardant's market position and credibility.

What critics are saying

  • Competition from companies like SOPHiA GENETICS may impact market share.
  • Integration challenges with ConcertAI could delay benefits from their partnership.
  • Potential regulatory hurdles may affect the commercialization timeline of new diagnostics.

What makes Guardant Health unique

  • Guardant Health specializes in blood-based tests for comprehensive cancer management.
  • Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
  • Partnerships with ConcertAI and COTA enhance their data-driven oncology solutions.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$2137.8M

Above

Industry Average

Funded Over

8 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Professional Development Budget

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Asian Hospital & Healthcare Management
Jan 17th, 2025
Guardant Health and ConcertAI Partner to Launch Data-as-a-Service Platform Integrating Clinical and Tumour Profiling Data to Speed Up Cancer Therapy Research and Development

Guardant Health, a leading precision oncology company, has entered into a collaboration with ConcertAI, an oncology real-world evidence (RWD) data and AI technology company.

Hit Consultant
Jan 17th, 2025
Guardant Health And Concertai Partner To Unlock Cancer Insights With Multi-Modal Real-World Data

What You Should Know:– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.Enhanced Cancer Research and DevelopmentCancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression. Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread. Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies

Guardant Health
Jan 2nd, 2025
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

HC Data
Dec 19th, 2024
COTA and Guardant Health Partner to Advance Precision Oncology with AI and Real-World Data

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).

GenomeWeb
Dec 18th, 2024
Guardant Health, Boehringer Ingelheim Partner on Companion Diagnostic for New Lung Cancer Drug

NEW YORK - Guardant Health said Wednesday that it has entered into a collaboration with Boehringer Ingelheim to pursue regulatory approval and commercialization of its Guardant360 CDx liquid biopsy assay as a companion diagnostic for Boehringer's investigational drug zongertinib in lung cancer.

Recently Posted Jobs

Sign up to get curated job recommendations

Guardant Health is Hiring for 84 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Guardant Health's jobs every few hours, so check again soon! Browse all jobs →